Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib (IPI-145) in combination with rituximab or obinutuzumab in previously untreated CD20+ follicular lymphoma
2014-005459-13Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of duvelisib in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Primary Endpoint (Part 1). Started May 2015; status: completed.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2014-005459-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005459-13.